MEF2C controls lysosomal and lipid clearance programs linked to Alzheimer's disease risk in macrophages
Alison Goate1, Anna Podlesny-Drabiniok1,2,3, Jeanne Kim1,4,5
1Ronald M. Loeb Center for Alzheimer's Disease, Department of Genetics & Genomic Sciences, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, New York, NY 10029, USA.
Abstract:
Risk alleles for late-onset Alzheimer's disease (AD) are enriched in myeloid cis-regulatory elements, implicating myeloid gene-regulatory networks in disease susceptibility. A conserved lipid-associated transcriptional signature-spanning disease-associated microglia and peripheral lipid-associated macrophages (DLAM)-emerges across neurodegenerative and metabolic diseases characterized by lipid overload, yet the transcriptional regulators of this gene expression program remain incompletely defined. Here, we show that MEF2C-a candidate AD risk gene-is a master DLAM regulator. Using MEF2C knockout and knockdown in human iPSC-derived microglia and macrophages, we found that total or partial MEF2C loss is sufficient to induce DLAM-associated transcriptional, epigenomic, and functional remodeling, including enhanced lysosomal activity and cholesterol efflux. Integration of chromatin accessibility and regulatory epigenetic profiles with functionally informed fine-mapping linked candidate causal variants in AD risk loci to MEF2C-regulated cis-regulatory elements that target candidate AD risk genes at these loci. In a triculture model of AD, microglial MEF2C loss is associated with an increased DLAM population and a reduced Aβ42/40 ratio, supporting context-dependent reprogramming of microglia as a potential biological mechanism to modulate AD-relevant pathology.
Insights
MEF2C is a key regulator of lipid metabolism in brain immune cells, influencing Alzheimer's disease (AD) risk. Loss of MEF2C promotes a disease-associated macrophage phenotype, potentially modulating AD pathology.
Area of Science:
- Neuroimmunology
- Genetics
- Molecular Biology
Background:
- Alzheimer's disease (AD) risk alleles are linked to myeloid cell gene regulation.
- A lipid-associated transcriptional signature (DLAM) is observed in neurodegenerative diseases, but its regulators are unclear.
Purpose of the Study:
- To identify master regulators of the DLAM transcriptional program.
- To investigate the role of MEF2C, a candidate AD risk gene, in DLAM regulation and AD pathology.
Main Methods:
- MEF2C knockout and knockdown in human iPSC-derived microglia and macrophages.
- Analysis of transcriptional, epigenomic, and functional changes.
- Integration of chromatin accessibility, epigenetic profiles, and fine-mapping.
- Assessment in a triculture model of AD.
Main Results:
- MEF2C loss induces DLAM-associated transcriptional, epigenomic, and functional changes, including increased lysosomal activity and cholesterol efflux.
- Candidate AD risk variants are linked to MEF2C-regulated elements targeting AD risk genes.
- Microglial MEF2C loss increases DLAM population and reduces Aβ42/40 ratio in an AD model.
Conclusions:
- MEF2C is a master regulator of the DLAM program in myeloid cells.
- MEF2C plays a significant role in modulating AD-relevant pathology through microglial reprogramming.
Related Concept Videos
Master Transcription Regulators
Lysosomal Hydrolases
Alzheimer Disease ll: Pathophysiology

